作者
Gian Paolo Fadini, Elisa Boscaro, Mattia Albiero, Lisa Menegazzo, Vera Frison, Saula De Kreutzenberg, Carlo Agostini, Antonio Tiengo, Angelo Avogaro
发表日期
2010/7/1
期刊
Diabetes care
卷号
33
期号
7
页码范围
1607-1609
出版商
American Diabetes Association
简介
OBJECTIVE
Vasculoprotective endothelial progenitor cells (EPCs) are regulated by stromal-derived factor-1α (SDF-1α) and are reduced in type 2 diabetes. Because SDF-1α is a substrate of dipeptidyl-peptidase-4 (DPP-4), we investigated whether the DPP-4 inhibitor sitagliptin modulates EPC levels in type 2 diabetic patients.
RESEARCH DESIGN AND METHODS
This was a controlled, nonrandomized clinical trial comparing 4-week sitagliptin (n = 16) versus no additional treatment (n = 16) in addition to metformin and/or secretagogues in type 2 diabetic patients. We determined circulating EPC levels and plasma concentrations of SDF-1α, monocyte chemoattractant protein-1 (MCP-1), vascular endothelial growth factor (VEGF), and nitrites/nitrates.
RESULTS
There was no difference in clinical baseline data between the sitagliptin and control arms. After 4 weeks …
引用总数
学术搜索中的文章
GP Fadini, E Boscaro, M Albiero, L Menegazzo… - Diabetes care, 2010